Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Interest & Investment Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Interest & Investment Income for 3 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income fell 38.35% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.2 million, a 26.84% decrease, with the full-year FY2024 number at $10.9 million, down 8.2% from a year prior.
  • Interest & Investment Income was $1.8 million for Q3 2025 at Inhibrx Biosciences, down from $2.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.3 million in Q1 2024 to a low of $1.8 million in Q3 2025.
  • A 3-year average of $2.4 million and a median of $2.3 million in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: rose 24.44% in 2024, then plummeted 38.35% in 2025.
  • Inhibrx Biosciences' Interest & Investment Income stood at $2.3 million in 2023, then dropped by 13.81% to $2.0 million in 2024, then fell by 10.98% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Interest & Investment Income are $1.8 million (Q3 2025), $2.1 million (Q2 2025), and $2.3 million (Q1 2025).